About Glyphic Biotechnologies
Glyphic Biotechnologies is a company based in San Francisco (United States) founded in 2021 by Daniel Estandian and Joshua Yang. Glyphic Biotechnologies has raised $39.2 million across 6 funding rounds from investors including HHS, OMX Ventures and Trevor Martin. The company has 26 employees as of December 31, 2024. Glyphic Biotechnologies operates in a competitive market with competitors including Somalogic, Nautilus Biotechnology, Amunix, Biognosys and Elektrofi, among others.
- Headquarter San Francisco, United States
- Employees 26 as on 31 Dec, 2024
- Founders Daniel Estandian, Joshua Yang
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Glyphic Biotechnologies, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$39.2 M (USD)
in 6 rounds
-
Latest Funding Round
Not available
-
Investors
HHS
& 9 more
-
Employee Count
26
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Glyphic Biotechnologies
Unlock access to complete
Funding Insights of Glyphic Biotechnologies
Glyphic Biotechnologies has successfully raised a total of $39.2M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Glyphic Biotechnologies
Glyphic Biotechnologies has secured backing from 10 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include HHS, OMX Ventures and Trevor Martin.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are made in transformative biotech companies by OMX Ventures.
|
Locked | Locked | Locked | |
|
Early- to growth-stage startups are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Venture capital fund and fund of funds focused on early-stage startups
|
Locked | Locked | Locked |
Investor details for Glyphic Biotechnologies
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Glyphic Biotechnologies
Investment portfolio details for Glyphic Biotechnologies
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Glyphic Biotechnologies
Detailed financials for Glyphic Biotechnologies
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Glyphic Biotechnologies Comparisons
Peer comparison for Glyphic Biotechnologies
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Glyphic Biotechnologies
Glyphic Biotechnologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Somalogic, Nautilus Biotechnology, Amunix, Biognosys and Elektrofi, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Protein-based assays are developed for life science research.
|
|
| Locked | Locked | Locked |
A proteomics platform is developed for analyzing the human proteome.
|
|
| Locked | Locked | Locked |
Peptide-based therapeutics are developed for cancers and immune disorders.
|
|
| Locked | Locked | Locked |
Proteomics services are delivered via discovery and targeted platforms.
|
|
| Locked | Locked | Locked |
Digital platform transforming the delivery of biologic medicines
|
|
| Locked | Locked | Locked |
Provider tools to help researchers with protein analysis
|
Detailed competitors of Glyphic Biotechnologies
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Glyphic Biotechnologies
Complete news archive for Glyphic Biotechnologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Glyphic Biotechnologies
Glyphic Biotechnologies was founded in 2021.
Glyphic Biotechnologies is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Joshua Yang is the current CEO of Glyphic Biotechnologies. They have also founded this company.
Glyphic Biotechnologies is a funded company, having raised a total of $39.2M across 6 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Glyphic Biotechnologies is 26.
Glyphic Biotechnologies was founded in 2021 in San Francisco, United States, within the biotechnology sector. A platform for next-generation protein sequencing is offered, focusing on de novo sequencing at single-molecule resolution. The human proteome is decoded through these methods, allowing researchers to explore biology and disease mechanisms. Operations center on enabling novel insights via advanced sequencing technologies.
Glyphic Biotechnologies's top competitors include Somalogic, Nautilus Biotechnology and Elektrofi.
Glyphic Biotechnologies has 10 investors. Key investors include HHS, OMX Ventures, Trevor Martin, Osage University Partners, and Wing Venture Capital.